A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy

Invest New Drugs. 1986;4(3):241-4. doi: 10.1007/BF00179590.

Abstract

Forty-two patients were entered into a phase I trial to evaluate the vitamin A derivative, trans-retinoic acid, in cervical intraepithelial neoplasia. Treatment consisted of four consecutive 24-h applications of retinoids via an inert collagen sponge in a cervical cap. Patients were followed for response at 3-month intervals using cytology, colposcopy, and selected biopsies. Thirty-six patients were evaluable (mild dysplasia, 13; moderate dysplasia, 17; severe dysplasia, 6) with follow-up from 5 to 18 months. Complete regression was seen in 2/14 (14%) patients treated with concentrations of 0.05%----0.1167% and in 10/22 (45%) patients treated with concentrations of 0.1583%----0.484% (p less than 0.05). One patient with negative biopsies at 12 months has subsequently recurred at 18 months.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Topical
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Female
  • Humans
  • Tretinoin / therapeutic use*
  • Uterine Cervical Dysplasia / drug therapy*

Substances

  • Tretinoin